Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ProfusaPFSA -4.82%8 3-Year EBITDA Growth Rate is -48.80% as of Mar. 2026. GuruFocus rates PFSA with a GF Score™ of 8/100. The stock has 3 warning signs investors should review. Among 692 Medical Devices & Instruments companies, Profusa ranks worse than 95.66% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was -48.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 5 years, the highest 3-Year average EBITDA Per Share Growth Rate of Profusa was 1.60% per year. The lowest was -48.80% per year. And the median was -23.60% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Profusa 3-Year EBITDA Growth Rate Related Terms
PFSA vs VTAK, RBOT, NUWE: 3-Year EBITDA Growth Rate Comparison
For the Medical Devices subindustry, Profusa's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Profusa 3-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Profusa's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Profusa's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of -48.80% mean?
Profusa (PFSA) has a 3-Year EBITDA Growth Rate of -48.80% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Profusa and its competitors. According to the industry distribution chart, Profusa ranks #662 out of 692 companies in the Medical Devices & Instruments industry, placing it in the top 95.7%.
Is Profusa's 3-Year EBITDA Growth Rate too high?
Profusa's current 3-Year EBITDA Growth Rate is -48.80%. Based on the distribution chart, Profusa ranks #662 out of 692 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Profusa has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Profusa's 3-Year EBITDA Growth Rate compare to VTAK and RBOT?
According to the Medical Devices & Instruments industry distribution chart, Profusa ranks #662 out of 692 companies for 3-Year EBITDA Growth Rate. This places Profusa in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 8.20. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EBITDA Growth Rate among Medical Devices & Instruments companies is 8.20, based on 692 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Profusa and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EBITDA Growth Rate is 8.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Profusa's current 3-Year EBITDA Growth Rate is -48.80%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Profusa stock overvalued right now?
Profusa (PFSA) has a current 3-Year EBITDA Growth Rate of -48.80%. The current 3-Year EBITDA Growth Rate is -48.80%. Profusa's overall GF Score™ is 8/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Profusa (PFSA), the current 3-Year EBITDA Growth Rate is -48.80% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Profusa Inc is a clinical-stage digital health and medical technology company. The Company's technology enables the development of bioengineered sensors that are designed to become one with the body to detect and continuously transmit actionable, clinical-grade data for personal and medical use. The Company's first offering in the European Union, the Lumee Oxygen Platform, is designed to report reliable tissue oxygen levels at various regions of interest, both acutely and long-term. The Lumee Oxygen Platform has been designed for use in applications where monitoring of compromised tissue is beneficial, such as peripheral artery disease that results in narrowing of blood vessels and reduced blood flow to the lower limbs; chronic wounds that do not heal properly; and reconstructive surgery.
8GF Score
Get the complete analysis for PFSA
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PFSA has been successfully added to your 
